Oct 08, 2019
Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
Sep 12, 2019
Menarini: Elcin Barker Ergun Group CEO
Sep 10, 2019
EMD Serono Initiates Pivotal Phase III Program for Investigational Evobrutinib in Relapsing Multiple Sclerosis
Aug 28, 2019
EMD Serono to Showcase Scientific Leadership at ECTRIMS 2019 with New Data Across Multiple Sclerosis Medicines
Jun 20, 2019
Massachusetts-based Business Sectors of Merck KGaA, Darmstadt, Germany Named 'Best Places to Work' by Boston Business Journal
Jun 03, 2019
Merck KGaA, Darmstadt, Germany Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations
May 28, 2019
EMD Serono to Present Data at CMSC Annual Meeting Showcasing Breadth of MS Portfolio and Commitment to Understanding How MS Impacts Patients
May 22, 2019
Experts Discuss Decentralized Manufacturing to Tackle Neglected Tropical Diseases and Promote Universal Health Coverage at World Health Assembly Event
May 10, 2019
Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton's Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS
May 07, 2019
EMD Serono Launches MS-LINK(TM), a Community to Advance MS Science and Improve Patient Lives
May 06, 2019
Intermolecular to be acquired by Merck KGaA, Darmstadt, Germany for $1.20 per share in an all cash transaction
Apr 30, 2019
EMD Serono to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
Apr 12, 2019
Merck KGaA, Darmstadt, Germany, Signs Definitive Agreement to Acquire Versum Materials for $53 per Share
Apr 08, 2019
MAVENCLAD® (Cladribine) Tablets Now Covered by Express Scripts
Apr 05, 2019
Elmar Schnee and Diane Parks Proposed as New Board Members of Calliditas Therapeutics
Apr 03, 2019
EvoNexus Technology Incubator in Partnership with EMD Performance Materials is Accepting Applications to Admit New Startups
Mar 29, 2019
FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
Mar 14, 2019
Merck Announces Collaboration With Iktos for Generative Artificial Intelligence (AI) Technology
Mar 14, 2019
Merck KGaA, Darmstadt, Germany, Announces Collaboration With Iktos for Generative Artificial Intelligence (AI) Technology
Feb 28, 2019
EMD Serono to Present Multiple Sclerosis Data on Cladribine Tablets and Evobrutinib at ACTRIMS 2019